Abstract
Pancreatic ductal adenocarcinoma (PDAC) reflects the current challenge for immuno-oncology: to develop new drugs for cancers that are resistant to current immunotherapies. Here, we argue for a need to use patients to uncover new strategies that activate anti-tumour immunity.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents, Immunological / therapeutic use
-
Carcinoma, Pancreatic Ductal / genetics
-
Carcinoma, Pancreatic Ductal / immunology*
-
Carcinoma, Pancreatic Ductal / therapy
-
Disease Models, Animal
-
Humans
-
Immunotherapy
-
Mice
-
Pancreatic Neoplasms / genetics
-
Pancreatic Neoplasms / immunology*
-
Pancreatic Neoplasms / therapy
Substances
-
Antineoplastic Agents, Immunological